Table 3.
Diagnostic work-up summary of CUP cohort.
| Patient Characteristics | Total patients (%), N=305 | Unidentified primary (%), N=196 | Identified primary (%), N=109 | P-value |
|---|---|---|---|---|
| Documented Patient History | 304 (99.7) | 195 (99.5) | 109 (100) | >0.999 |
| Documented Physical Examination | 298 (97.7) | 191 (97.4) | 107 (98.2) | >0.999 |
| Bloodwork | ||||
| Complete Blood Count | 303 (98.0) | 194 (99.0) | 109 (100) | 0.593 |
| Lactase Dehydrogenase (LD/LDH) | 161 (52.8) | 100 (51.0) | 61 (56.0) | 0.473 |
| Creatinine | 305 (100) | 196 (100) | 109 (100) | 0.178 |
| Electrolytes | 299 (98.0) | 191 (97.4) | 108 (99.1) | 0.282 |
| Calcium | 265 (86.9) | 169 (86.2) | 96 (88.1) | 0.784 |
| Alpha Fetoprotein (midline metastatic sites only, n=241) | 58 (24.0) | 35 (22.2) | 23 (27.8) | 0.346 |
| Beta human chorionic gonadotropin (midline metastatic sites only, n=244) | 33 (13.5) | 19 (11.8) | 14 (16.9) | 0.324 |
| Plasma Chromogranin A (neuroendocrine tumors only, n=51) | 21 (41.2) | 18 (46.2) | 3 (25.0) | 0.315 |
| Prostate-Specific Antigen (male with bone metastases only, n=41) | 24 (58.5) | 16 (61.5) | 8 (53.3) | 0.719 |
| Immunohistochemistry (IHC) | ||||
| CK7 | 229 (75.1) | 144 (73.5) | 85 (78.0) | |
| CK20 | 226 (74.1) | 142 (72.4) | 84 (77.1) | |
| Adherence to published IHC diagnostic guidelines | ||||
| No | 89 (29.2) | 59 (30.1) | 30 (27.5) | |
| CK7 and CK20 only | 65 (21.3) | 47 (24.0) | 18 (16.5) | |
| Partial adherence to additional markers | 146 (47.9) | 88 (44.9) | 58 (53.2) | |
| Complete adherence to additional markers | 5 (1.6) | 2 (1.0) | 3 (2.8) | |
| Imaging/Diagnostic Tests | ||||
| CT Head | 181 (59.3) | 113 (57.7) | 68 (62.4) | 0.467 |
| CT Thorax | 293 (96.1) | 187 (95.4) | 106 (97.3) | 0.548 |
| CT Abdomen/Pelvis | 291 (95.4) | 188 (95.9) | 103 (94.5) | 0.578 |
| Octreoscan (neuroendocrine tumors only, n=49) | 19 (38.8) | 14 (38.9) | 5 (38.5) | >0.999 |
| Mammography (female only, n=148) | 50 (33.8) | 29 (31.5) | 21 (37.5) | 0.478 |
| Endoscopy | 121 (39.7) | 80 (40.8) | 41 (37.6) | 0.716 |
| Positron Emission Transmission (PET) Scan (cervical or single-site tumors only, n=117) | 24 (20.5) | 14 (17.9) | 10 (25.6) | 0.238 |
| Next Generation Sequencing (NGS) | 5 (1.6) | 3 (1.5) | 2 (1.8) | >0.999 |